Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Natera presented new Signatera clinical data at the ASTRO 2026 annual meeting, showing its monitoring flagged patients at higher risk of relapse after chemoradiation or radiotherapy. Data also supported organ-preservation strategies by identifying patients likely to remain disease-free under surveillance. Results were
Natera, Inc. announced new data presented at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting. Four oral presentations demonstrated Signatera's role in informing personalized care management, including radiotherapy treatments.
Natera, Inc. announced new data presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, marking its first participation at the conference. The data highlighted the utility of its Signatera™ test for radiation oncologists.